“Glucagon-like Peptide Receptor Agonists (GLP-1 receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients with Type 2 Diabetes Mellitus”, Can Diabetes Endocrinol Today, vol. 2, no. 3, pp. 31–35, Nov. 2024, doi: 10.58931/cdet.2024.2333.